AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients TAIPEI, May 22, 2025 /PRNewswire/ — AnnJi Pharmaceutical Co., Ltd., a clinical-stage… May 22, 2025
Marketplace Battle Heats Up: Trust, Convenience and Choice Key as Pricing Pressures Grow MELBOURNE , Australia, May 22, 2025 /PRNewswire/ — An exclusive Australian study… May 22, 2025
Prime Focus Technologies expands Southeast Asia presence with strategic partnerships in Indonesia and the Philippines LOS ANGELES, May 22, 2025 /PRNewswire/ — Prime Focus Technologies (PFT), the… May 22, 2025
Huntsman Corporation Announces New Purification and Packaging Capability through its E-GRADE® Unit in Conroe, Texas THE WOODLANDS, Texas, May 22, 2025 /PRNewswire/ — Huntsman Corporation (NYSE: HUN),… May 22, 2025
RD Technologies Celebrates Passage of Stablecoins Ordinance in Hong Kong HONG KONG, May 22, 2025 /PRNewswire/ — RD Technologies, a Hong Kong-based… May 22, 2025
Prime Focus Technologies expands Southeast Asia presence with strategic partnerships in Indonesia and the Philippines LOS ANGELES, May 22, 2025 /PRNewswire/ — Prime Focus Technologies (PFT), the… May 22, 2025
Weichai's M-series large-bore engines reinforce their leadership in the global premium power sector SYDNEY, May 21, 2025 /PRNewswire/ — From May 16 to 18, Australia’s… May 22, 2025
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab)… May 22, 2025
